428 related articles for article (PubMed ID: 16934080)
1. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
3. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens.
Nosari A; Cairoli R; Ciapanna D; Gargantini L; Intropido L; Baraté C; Scarpati B; Santoleri L; Nador G; Pezzetti L; Morra E
Bone Marrow Transplant; 2006 Sep; 38(6):413-6. PubMed ID: 16878144
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients.
Isidori A; Tani M; Bonifazi F; Zinzani P; Curti A; Motta MR; Rizzi S; Giudice V; Farese O; Rovito M; Alinari L; Conte R; Baccarani M; Lemoli RM
Haematologica; 2005 Feb; 90(2):225-31. PubMed ID: 15710576
[TBL] [Abstract][Full Text] [Related]
6. The role of pegfilgrastim in mobilization of hematopoietic stem cells.
Kroschinsky F; Hölig K; Ehninger G
Transfus Apher Sci; 2008 Jun; 38(3):237-44. PubMed ID: 18490197
[TBL] [Abstract][Full Text] [Related]
7. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
[TBL] [Abstract][Full Text] [Related]
8. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
9. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
[TBL] [Abstract][Full Text] [Related]
10. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
11. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
12. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Assouline S; Sylvestre MP; Carriere P; Shustik C; Laneuville P
Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
Hosing C; Qazilbash MH; Kebriaei P; Giralt S; Davis MS; Popat U; Anderlini P; Shpall EJ; McMannis J; Körbling M; Champlin RE
Br J Haematol; 2006 Jun; 133(5):533-7. PubMed ID: 16681642
[TBL] [Abstract][Full Text] [Related]
16. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
17. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
[TBL] [Abstract][Full Text] [Related]
18. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
[TBL] [Abstract][Full Text] [Related]
19. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
20. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
Samaras P; Blickenstorfer M; Siciliano RD; Haile SR; Buset EM; Petrausch U; Mischo A; Honegger H; Schanz U; Stussi G; Stahel RA; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2011 Jan; 90(1):89-94. PubMed ID: 20706722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
